(Q34580738)

3 August 2017

1 reference

title

Genetic screening for SSRI drug response among those with major depression: great promise and unseen perils (English)

1 reference

3 August 2017

0 references

Laura J Rasmussen-Torvik

series ordinal

1

object named as

Laura J Rasmussen-Torvik

1 reference

3 August 2017

Donna D McAlpine

2

1 reference

3 August 2017

publication date

1 January 2007

1 reference

3 August 2017

published in

Depression and Anxiety

1 reference

3 August 2017

volume

24

1 reference

3 August 2017

issue

5

1 reference

3 August 2017

page(s)

350-357

1 reference

Medical ethics: four principles plus attention to scope

3 August 2017

cites work

1 reference

A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: II. Suicidal behavior

21 January 2018

1 reference

7 January 2021

Affective Disorders and Suicide Risk: A Reexamination

1 reference

7 January 2021

Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram

1 reference

7 January 2021

Discontinuation of use and switching of antidepressants: influence of patient-physician communication

1 reference

7 January 2021

Discontinuing or switching selective serotonin-reuptake inhibitors

1 reference

7 January 2021

Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice

1 reference

7 January 2021

Categorizing genetic tests to identify their ethical, legal, and social implications

1 reference

7 January 2021

Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene

1 reference

7 January 2021

Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram

1 reference

7 January 2021

Response, partial response, and nonresponse in primary care treatment of depression

1 reference

7 January 2021

The most expensive medical conditions in America.

1 reference

7 January 2021

St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4

1 reference

7 January 2021

Interactions between genetic predisposition and environmental toxicants for development of lung cancer

1 reference

7 January 2021

Cognitive-behavioral management of drug-resistant major depressive disorder

1 reference

7 January 2021

Diagnosis and definition of treatment-resistant depression

1 reference

7 January 2021

Definition and epidemiology of treatment-resistant depression

1 reference

7 January 2021

Economic implications of treatment-resistant depression among employees.

1 reference

7 January 2021

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

1 reference

7 January 2021

PCR-based genotyping for duplicated and deleted CYP2D6 genes

1 reference

7 January 2021

Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study

1 reference

7 January 2021

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

1 reference

7 January 2021

Serotonin transporter gene polymorphism and antidepressant response

1 reference

7 January 2021

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

1 reference

7 January 2021

Sequence analysis of the serotonin transporter and associations with antidepressant response

1 reference

7 January 2021

Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis

1 reference

7 January 2021

Pharmacogenetics of psychotropic drug response

1 reference

7 January 2021

Pharmacogenetics of antidepressant medication intolerance

1 reference

7 January 2021

The apolipoprotein E ε4 allele and antidepressant efficacy in cognitively intact elderly depressed patients

1 reference

7 January 2021

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

1 reference

7 January 2021

Pharmacogenetic testing, informed consent and the problem of secondary information

1 reference

7 January 2021

Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6

1 reference

7 January 2021

CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study

1 reference

7 January 2021

Naturalistic study of the early psychiatric use of citalopram in the United States.

1 reference

7 January 2021

Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design

1 reference

7 January 2021

The pharmacogenomics of selective serotonin reuptake inhibitors.

1 reference

7 January 2021

Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review.

1 reference

7 January 2021

CYP1A1andCYP2D6polymorphism and risk of lung cancer in a North Indian population

1 reference

7 January 2021

Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents

1 reference

7 January 2021

Five-year impact of quality improvement for depression: results of a group-level randomized controlled trial.

1 reference

7 January 2021

Functioning and utility for current health of patients with depression or chronic medical conditions in managed, primary care practices.

1 reference

7 January 2021

Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients.

1 reference

7 January 2021

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

1 reference

7 January 2021

Identifiers

DOI

10.1002/DA.20251

1 reference

3 August 2017

1 reference